<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30652743</article-id><article-id pub-id-type="pmc">6326436</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0139</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Vasodilatory Efficacy and Impact of Papaverine on Endothelium in
Radial Artery Predilatation for CABG Surgery: in Search for Optimal
Concentration</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>W&#x00119;grzyn</surname><given-names>Piotr</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="fn1">*</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Lis</surname><given-names>Grzegorz</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="fn1">*</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Rudzinski</surname><given-names>Pawe&#x00142;</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Piatek</surname><given-names>Jacek</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Pyka-Fosciak</surname><given-names>Grazyna</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Korbut</surname><given-names>Ryszard</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Kapelak</surname><given-names>Boguslaw</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Bartus</surname><given-names>Krzysztof</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Litwinowicz</surname><given-names>Radoslaw</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD, PhD</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Cardiovascular Surgery and Transplantology, John Paul
II Hospital, Jagiellonian University Medical College, Krakow, Poland.</aff><aff id="aff2">
<label>2</label> Department of Histology, Jagiellonian University Medical College,
Krakow, Poland.</aff><aff id="aff3"><label>3</label> Department of Pharmacology, Jagiellonian University
Medical College, Krakow, Poland.</aff><author-notes><corresp id="c1">Correspondence Address: Radoslaw Litwinowicz, Department of
Cardiovascular Surgery and Transplantology, John Paul II Hospital,
Pr&#x00105;dnicka 80, Krakow, Poland, Zip Code: 31-202. E-mail:
<email>radek.litwinowicz@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Nov-Dec</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2018</year></pub-date><volume>33</volume><issue>6</issue><fpage>553</fpage><lpage>558</lpage><history><date date-type="received"><day>14</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>20</day><month>7</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>The aim of this study was to compare the efficacy of two different papaverine
concentrations (0.5 mg/ml and 2 mg/ml) for vasospasm prevention and their
impact on endothelium integrity.</p></sec><sec><title>Methods</title><p>We have studied distal segments of radial arteries obtained by no-touch
technique from coronary artery bypass graft (CABG) patients (n=10). The
vasodilatory effect of papaverine (concentrations of 0.5 mg/ml and 2 mg/ml)
was assessed <italic>in vitro</italic>, in isometric tension studies using
<italic>ex vivo</italic> myography (organ bath technique) and arterial
rings precontracted with potassium chloride (KCl) and phenylephrine. The
impact of papaverine on endothelial integrity was studied by measurement of
the percentage of vessel's circumference revealing CD34 endothelial
marker.</p></sec><sec><title>Results</title><p>2 mg/ml papaverine concentration showed stronger vasodilatatory effect than
0.5 mg/ml, but it caused significantly higher endothelial damage. Response
to KCl was 7.35&#x000b1;3.33 mN for vessels protected with papaverine 0.5
mg/ml and 2.66&#x000b1;1.96 mN when papaverine in concentration of 2 mg/ml
was used. The histological examination revealed a significant difference in
the presence of undamaged endothelium between vessels incubated in
papaverine 0.5 mg/ml (72.86&#x000b1;9.3%) and 2 mg/ml (50.23&#x000b1;13.42%),
<italic>P</italic>=0.002.</p></sec><sec><title>Conclusion</title><p>Papaverine 2 mg/ml caused the higher endothelial damage. Concentration of 0.5
mg/ml caused better preservation of the endothelial lining.</p></sec></abstract><kwd-group><kwd>Vasodilation</kwd><kwd>Coronary Artery Bypass</kwd><kwd>Radial Artery</kwd><kwd>Papaverine</kwd><kwd>Graft Occlusion, Vascular</kwd></kwd-group></article-meta></front><body><table-wrap id="t2" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="38%" span="1"/><col width="05%" span="1"/><col width="10%" span="1"/><col width="37%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#eaeaea" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="2" style="background-color:#eaeaea" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ANOVA</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Analysis of
variance</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>LIMA</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Left internal
mammary artery</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>BMI</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Body mass
index</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>NO</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Nitric
oxide</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CABG</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Coronary artery
bypass graft</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>PBS</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Phosphate-buffered
saline</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CCS</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Canadian
Cardiovascular Society</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>PDE</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>=
Phosphodiesterase</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>cGMP</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Cyclic guanosine
monophosphate</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>PE</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>=
Phenylephrine</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CK-MB</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Creatine
kinase-muscle/brain</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>RA</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Radial
artery</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>KCl</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Potassium
chloride</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>RAPCO</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Radial Artery
Patency and Clinical Outcomes</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ICU</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Intensive care
unit</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>RCA</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Right coronary
artery</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>LAD</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Left artery
descending</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>SD</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Standard
deviation</bold></td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Coronary artery bypass graft (CABG) surgery is the most common cardiac surgical
procedure that presents long term efficacy and durability with reduced mortality and
morbidity observed in the last decade<sup>[<xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r3" ref-type="bibr">3</xref>]</sup>. For many
years, left internal mammary artery (LIMA) has been routinely applied in CABG
surgery as "first conduit of choice" because of its resistance to atherosclerosis,
especially in older patients<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Radial artery (RA) is rarely used as a conduit in CABG
surgery, mainly because of its high tendency to vasospasm. However, the durability
of RA as an arterial conduit is satisfactory: according to Acar et
al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>,
patency rates were 93% after 9 months and 89% after 2 years. RA shows higher failure
rates when grafted to right coronary artery (RCA) system than to left artery
descending (LAD) system. The failures should rather be attributed to the coronary
artery than to the RA conduit because of the higher intensity of atherosclerosis in
RCA<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>RA can be applied as a classic conduit or Y-graft, with the proximal site connected
with LAD and the distal site grafted into coronary artery. Comparing RA grafts
durability with that of veins, RA is much more suitable for CABG: after 5 years of
follow-up, the patency of vessels was 98% <italic>vs</italic>. 86%<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>. Ferrari and
Segesser<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>
recommended RA as the "second conduit of choice", after the internal mammary artery,
in CABG. Furthermore, it is worth to mention that according to mid-term outcomes in
the Radial Artery Patency and Clinical Outcomes (RAPCO) trial<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>, there was no essential
difference both in patients' free survival time and graft patency time between RA
and right internal thoracic artery.</p><p>Several techniques are available for bypass graft vessel predilatation during CABG
surgery. With an increasing use of RA as a graft, it is very important to understand
how the predilatation process can be pharmacologically controlled to improve graft
function. We have already compared the vasodilatory effect and impact on endothelium
of milrinone 0.4 mg/ml and papaverine 1 mg/ml<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Our previously research revealed that
papaverine in concentration of 1 mg/ml exerts stronger vasodilatory effect on RA and
reveals lesser damaging influence on its endothelial cells compared to milrinone 0.4
mg/ml<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.
Taking into consideration these results, we continued the study comparing another
two different doses of papaverine - two times lower (0.5 mg/ml) and two times higher
(2 mg/ml).</p><p>The aim of this research was to examine the vasodilatory potential and effect of
different concentrations of papaverine on the endothelial integrity in the model of
RA segments harvested from CABG patients.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Patients</title><p>We have examined 10 RA segments harvested from patients who underwent CABG
surgery. Clinical characteristics as body mass index (BMI), Canadian
Cardiovascular Society (CCS) scale, atherosclerosis risk factors, myocardial
infarction, and atrial fibrillation were taken into consideration and presented
in <xref rid="t1" ref-type="table">Table 1</xref>. All patients signed the
written consent to participate in the study.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patients&#x02019; clinical characteristics.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="32%" span="1"/><col width="33%" span="1"/><col width="35%" span="1"/></colgroup><thead><tr><th align="center" colspan="2" rowspan="1">Patients&#x02019; characteristics</th><th align="center" rowspan="1" colspan="1">Average &#x000b1; SD or n (%)</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">67.5&#x000b1;4.95</td></tr><tr><td align="left" colspan="2" rowspan="1">Systolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">135&#x000b1;7.82</td></tr><tr><td align="left" colspan="2" rowspan="1">Diastolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">86.5&#x000b1;4.84</td></tr><tr><td align="left" colspan="2" rowspan="1">BMI (kg/m&#x000b2;)</td><td align="center" rowspan="1" colspan="1">27.51&#x000b1;1.18</td></tr><tr><td align="left" colspan="2" rowspan="1">CK-MB</td><td align="center" rowspan="1" colspan="1">38.1&#x000b1;32.56</td></tr><tr><td align="left" colspan="2" rowspan="1">Hospitalization (days)</td><td align="center" rowspan="1" colspan="1">8.8&#x000b1;1.93</td></tr><tr><td align="left" colspan="2" rowspan="1">ICU (days)</td><td align="center" rowspan="1" colspan="1">2.1&#x000b1;1.2</td></tr><tr><td align="left" colspan="2" rowspan="1">Post-surgical drainage (ml)</td><td align="center" rowspan="1" colspan="1">779&#x000b1;469.88</td></tr><tr><td align="left" colspan="2" rowspan="1">Blood unit transfusion (number)</td><td align="center" rowspan="1" colspan="1">2.3&#x000b1;1.7</td></tr><tr><td align="left" rowspan="2" colspan="1">Gender</td><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">1 (10%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">9 (90%)</td></tr><tr><td align="left" rowspan="3" colspan="1">CCS scale</td><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">2 (20%)</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">7 (70%)</td></tr><tr><td align="left" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">1 (10%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Smoking</td><td align="center" rowspan="1" colspan="1">5 (50%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Arterial hypertension</td><td align="center" rowspan="1" colspan="1">8 (80%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">7 (70%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Myocardial infarction</td><td align="center" rowspan="1" colspan="1">2 (20%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">7 (70%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Pressor drugs</td><td align="center" rowspan="1" colspan="1">10 (100%)</td></tr><tr><td align="left" colspan="2" rowspan="1">Rethoracotomy</td><td align="center" rowspan="1" colspan="1">1 (10%)</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><p>BMI=body mass index; CCS=Canadian Cardiovascular Society;
CK-MB=creatine kinase-muscle/brain; ICU=intensive care unit;
SD=standard deviation</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Arterial Rings</title><p>Each vessel ring obtained during CABG surgery was cut into six or four smaller
rings which were then exposed to organ bath (n=24) and histological examination
(n=20).</p></sec><sec><title>Organ Bath</title><p>Organ bath experiments were carried out according to standards described
previously<sup>[<xref rid="r10" ref-type="bibr">10</xref>-<xref rid="r13" ref-type="bibr">13</xref>]</sup>. The organ chamber was
filled with 5 ml of Krebs-Henseleit buffer, containing 120 mM NaCl, 4.7 mM
potassium chloride (KCl), 1.2 mM MgSO<sub>4</sub>, 1.2 mM KH<sub>2</sub>PO4, 2.5
mM CaCl<sub>2</sub>, 25 mM NaHCO<sub>3</sub>, and 5.5 mM glucose, at
37&#x000ba;C. The rings were mounted between two hooks and were strained to the
baseline value of 20 mN. Stabilization to 20 mN was done before each
measurement. The rings were precontracted with 20 mM KCl followed by increasing
concentrations (10<sup>-9</sup> to 10<sup>-2</sup>M) of phenylephrine (PE).
Next, they were rinsed, stabilized, and immersed in solutions of papaverine
(papaverinum hydrochloricum; Warszawskie Zak&#x00142;ady Farmaceutyczne Polfa
S.A., Karolkowa, Poland) at 0.5 mg/ml (n=12) or 2 mg/ml (n=12). The vasodilatory
effect was measured after 10, 20, 30, 40, 50, and 60 min, as described
previously<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. After stabilization, 20 mM KCl was added to the
chambers for 10 min to assess the spasm-preventing effect of papaverine. The
total amount of tested rings in organ bath were n=24. The AcomPC (Siemens,
Germany) software was used in all measurements.</p></sec><sec><title>Immunofluorescence and Morphometry</title><p>The method was the same as in the first part of research<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Twenty arterial rings
were immersed for 20 min in phosphate-buffered saline (PBS), in solutions of
papaverine 0.5 mg/ml (n=10) or 2 mg/ml (n=10), and then fixed in 4% buffered
formalin for 24 hours. After washing and freezing with PBS, 10 &#x000b5;m thick
cryostat sections were obtained and the influence of vasodilators on endothelial
integrity was studied by immunofluorescence. All 20 rings were serially
sectioned and used for immunohistochemical examination at every 20<sup>th</sup>
section. The sections were preincubated with 5% normal goat serum for 40 min,
and then were incubated overnight with endothelial cell marker, a mouse
monoclonal anti-CD34 antibody (dilution 1:50; Novocastra, Newcastle, UK).</p><p>Subsequently, sections were washed extensively in PBS and incubated for 90 min
with goat anti-mouse Cy-3-conjugated antibody (dilution 1:400; Jackson IR, West
Grove, PA, USA), and then the cell nuclei were counterstained with DAPI (Sigma,
Saint Louis, MO, USA). As previously, sections were washed three times in PBS
and mounted in glycerol/PBS solution on the same pH=8.6. As in the first part,
the endothelial integrity was expressed as the mean percentage of the lumen
perimeter immunopositive for CD34.</p></sec><sec><title>Statistical Analysis</title><p>Vasodilatory effects of two different papaverine concentrations were checked for
normal distribution with the Shapiro-Wilk test. All results obtained by organ
bath method and endothelial integrity measurements were expressed as mean
&#x000b1; standard deviation or median (interquartile range; Q1-25<sup>th</sup>
percentile and Q3-75<sup>th</sup> percentile) unless otherwise stated. To assess
the differences between two continuous variables, Student's t-test (for normally
distributed values) or the Mann-Whitney U test (for non-normally distributed
values) were applied. To assess the differences between three continuous
variables, analysis of variance (ANOVA) test (for normally distributed values)
or the Kruskal-Wallis test (for non-normally distributed values) were
applied.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>The mean vasorelaxation of precontracted RA was stronger in vessel rings incubated in
papaverine 2 mg/ml than in 0.5 mg/ml. The statistical significance was reached after
30 min of incubation (papaverine 0.5 mg/ml, 65.19&#x000b1;20.21 <italic>vs.</italic>
2 mg/ml, 89.86&#x000b1;10.45; <italic>P</italic>&#x0003c;0.001; <xref ref-type="fig" rid="f1">Figure 1</xref>). From the practical point of view, it means that the
appropriate efficacy is reached after half an hour. The vasorelaxative effect was
maintained until the end of vessel examination (60 min).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Vasodilatation of potassium chloride (KCl) precontracted radial artery
segments induced by papaverine 0.5 mg/ml (n=12) and 2 mg/ml (n=12).
Mean&#x000b1;SD. ***P&#x0003c;0.001; SD=standard deviation</p></caption><graphic xlink:href="rbccv-33-06-0553-g01"/></fig>
</p><p>The strongest inhibition of vasoconstriction induced by KCl was observed at the
highest papaverine dose (2.66&#x000b1;1.96 mN for 2 mg/ml <italic>vs</italic>.
7.35&#x000b1;3.33 mN for 0.5 mg/ml; <italic>P</italic>&#x0003c;0.001; <xref ref-type="fig" rid="f2">Figure 2</xref>).</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Potassium chloride (KCl) and phenylephrine induced contraction of radial
artery segments predilated by papaverine 0.5 mg/ml (n=12) and 2 mg/ml
(n=12). ***P=0.083.</p></caption><graphic xlink:href="rbccv-33-06-0553-g02"/></fig>
</p><p>We have also evaluated the impact of the examined papaverine concentration on
endothelial integrity by calculating the percentage of vessel's circumference lined
by endothelial cells, as revealed by immunofluorescence of their CD34 marker. The
endothelial integrity was better preserved after treatment of RA rings with
papaverine 0.5 mg/ml (72.86&#x000b1;9.3%) than with papaverine 2 mg/ml
(50.23&#x000b1;13.42 %, <italic>P</italic>=0.002) (<xref ref-type="fig" rid="f3">Figure 3</xref>).</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Representative micrographs showing endothelium (red) of radial artery
after treatment with papaverine 0.5 mg/ml (a) and 2 mg/ml (b). Note
progressive damage to the endothelial lining. Cell nuclei counterstained
by DAPI (blue). Bar = 200 &#x000b5;m.</p></caption><graphic xlink:href="rbccv-33-06-0553-g03"/></fig>
</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Our previous study has shown that when compared to milrinone, papaverine exerts a
stronger vasodilatory effect on RA segments and more effectively inhibits their
contractile response to KCl and PE. However some studies confirm the dual effect of
milrinone and other<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>]</sup> phosphodiesterase (PDE)
inhibitors, which reveals an additionally important inotropic effect in medical
treatment.</p><p>There is no unanimous standpoint concerning papaverine concentration that should be
applied in conduits predilatation. In many cardiovascular centers worldwide,
different doses of papaverine were examined and applied in predilatation of both RA
and internal mammary artery. The efficacy of papaverine was proved for different
doses: 0.4 mg/ml<sup>[<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref>]</sup>, 1 mg/ml<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, 2.5
mg/ml<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>,
and 4 mg/ml<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>.</p><p>At the Department of Cardiovascular Surgery and Transplantology, John Paul II
Hospital, where the investigation was carried out, the concentration of papaverine
applied for RA predilatation associated with CABG surgery was usually 2 mg/ml.</p><p>In terms of vasodilatation and further vasoprotection force, the efficacy of the 0.5
mg/ml papaverine concentration is much lower compared to the 2 mg/ml concentration,
and the effects of these two concentrations are comparable; from this viewpoint,
both concentrations should be taken under consideration for practical use in CABG
surgery. However, papaverine 2 mg/ml caused the highest endothelial damage, at the
level of almost 50%. Concentrations of 0.5 mg/ml resulted in much better
preservation of endothelial lining.</p><p>Immense damage of RA endothelium may lead to undesirable complications during the
first postoperative hours in intensive care unit (ICU) because of severe deficiency
of nitric oxide (NO), which is synthesized and secreted by endothelial cells. PDE
inhibitors increases intracellular cyclic guanosine monophosphate (cGMP) and, as
consequence, the level of NO as well<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. It is important to mention that, paradoxically,
excess level of PDE concentration causes endothelium destruction and, as a result,
lower NO secretion. This might cause a situation when a few hours after CABG
surgery, the vasorelaxative and vasoprotective effects of papaverine disappear and
the deficiency of NO, one of the most potent vasodilators which is crucial for the
regulation of the vascular tone, could lead to a sudden, uncontrolled RA spasm and
heart muscle ischemia, creating a direct health hazard with all its consequences for
the patient, including low output syndrome or sudden death.</p><p>Furthermore, the dysfunction of endothelium induces platelet activation releasing
thromboxane A2, which is conductive to thrombosis formation inside the
vessel<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>,
heightening complications in short post-operative period. To elude uncontrolled RA
vasospasm, appropriate no-touch harvesting technique and predilatation should be
applied. Additionally, it is worth to mention that using RA as a conduit following
radial access coronarography is controversial and should be
avoided<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>.</p><p>Thus, taking into consideration the safety (percentage of undamaged endothelium) and
our previous research<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>, papaverine at concentration 2 mg/ml should not be
applied in RA predilatation. The efficacy (maximum vasorelaxation force) of 1 mg/ml
examined in the first part of the research<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> is almost identical, but at that
concentration papaverine shows significantly better preservation of the endothelium.
On the other hand, KCl and PE induced contraction of RA segments predilated by 0.5
mg/ml and 1 mg/ml papaverine is stronger when compared with 2 mg/ml.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Papaverine at 0.5 mg/ml concentration seems to be more suitable than at 2 mg/ml for
prevention of vasospasm in RA conduits used for CABG. Papaverine at 2 mg/ml caused
the higher endothelial damage. Concentrations of 0.5 mg/ml caused better
preservation of the endothelial lining.</p><table-wrap id="t3" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1"><bold>Authors&#x02019; roles &#x00026;
responsibilities</bold></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">PW</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">GL</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">PR</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">JP</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">GPF</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">RK</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">BK</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">KB</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">RL</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Department of Cardiovascular Surgery and
Transplantology, John Paul II Hospital, Jagiellonian University Medical College,
Krakow, Poland.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="con" id="fn1"><label>*</label><p>Piotr W&#x00119;grzyn and Grzegorz Lis are the first authors of this manuscript
and have contributed equally to the content of this paper.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biancari</surname><given-names>F</given-names></name><name><surname>Ruggieri</surname><given-names>VG</given-names></name><name><surname>Perrotti</surname><given-names>A</given-names></name><name><surname>Svenarud</surname><given-names>P</given-names></name><name><surname>Dal&#x000e9;n</surname><given-names>M</given-names></name><name><surname>Onorati</surname><given-names>F</given-names></name><etal/></person-group><article-title>European Multicenter Study on Coronary Artery Bypass Grafting
(E-CABG registry): study protocol for a prospective clinical registry and
proposal of classification of postoperative complications</article-title><source>J Cardiothorac Surg</source><year>2015</year><volume>10</volume><fpage>90</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">26123033</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litwinowicz</surname><given-names>R</given-names></name><name><surname>Bartus</surname><given-names>K</given-names></name><name><surname>Drwila</surname><given-names>R</given-names></name><name><surname>Kapelak</surname><given-names>B</given-names></name><name><surname>Konstanty-Kalandyk</surname><given-names>J</given-names></name><name><surname>Sobczynski</surname><given-names>R</given-names></name><etal/></person-group><article-title>In-hospital mortality in cardiac surgery patients after
readmission to the intensive care unit: a single-center experience with
10,992 patients</article-title><source>J Cardiothorac Vasc Anesth</source><year>2015</year><volume>29</volume><issue>3</issue><fpage>570</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">26009285</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konstanty-Kalandyk</surname><given-names>J</given-names></name><name><surname>Piatek</surname><given-names>J</given-names></name><name><surname>Rudzinski</surname><given-names>P</given-names></name><name><surname>Wrobel</surname><given-names>K</given-names></name><name><surname>Bartus</surname><given-names>K</given-names></name><name><surname>Sadowski</surname><given-names>J</given-names></name></person-group><article-title>Clinical outcome of arterial myocardial revascularization using
bilateral internal thoracic arteries in diabetic patients: a single centre
experience</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2012</year><volume>15</volume><issue>6</issue><fpage>979</fpage><lpage>983</lpage><pub-id pub-id-type="pmid">22997249</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karthik</surname><given-names>S</given-names></name><name><surname>Srinivasan</surname><given-names>AK</given-names></name><name><surname>Grayson</surname><given-names>AD</given-names></name><name><surname>Jackson</surname><given-names>M</given-names></name><name><surname>Mediratta</surname><given-names>NK</given-names></name></person-group><article-title>Left internal mammary artery to the left anterior descending
artery: effect on morbidity and mortality and reasons for
nonusage</article-title><source>Ann Thorac Surg</source><year>2004</year><volume>78</volume><issue>1</issue><fpage>142</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">15223419</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acar</surname><given-names>C</given-names></name><name><surname>Jebara</surname><given-names>VA</given-names></name><name><surname>Portoghese</surname><given-names>M</given-names></name><name><surname>Beyssen</surname><given-names>B</given-names></name><name><surname>Pagny</surname><given-names>JY</given-names></name><name><surname>Grare</surname><given-names>P</given-names></name><etal/></person-group><article-title>Revival of the radial artery for coronary artery bypass
grafting</article-title><source>Ann Thorac Surg</source><year>1992</year><volume>54</volume><issue>4</issue><fpage>652</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">1358040</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatoulis</surname><given-names>J</given-names></name><name><surname>Buxton</surname><given-names>BF</given-names></name><name><surname>Fuller</surname><given-names>JA</given-names></name><name><surname>Meswani</surname><given-names>M</given-names></name><name><surname>Theodore</surname><given-names>S</given-names></name><name><surname>Powar</surname><given-names>N</given-names></name><etal/></person-group><article-title>Long-term patency of 1108 radial arterial-coronary angiograms
over 10 years</article-title><source>Ann Thorac Surg</source><year>2009</year><volume>88</volume><issue>1</issue><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">19559183</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>P</given-names></name><name><surname>Webb</surname><given-names>CM</given-names></name><name><surname>Chong</surname><given-names>CF</given-names></name><name><surname>Moat</surname><given-names>NE</given-names></name><collab>Radial Artery Versus Saphenous Vein Patency (RSVP) Trial
Investigators</collab></person-group><article-title>Radial artery versus saphenous vein patency randomized trial:
five-year angiographic follow-up</article-title><source>Circulation</source><year>2008</year><volume>117</volume><issue>22</issue><fpage>2859</fpage><lpage>2864</lpage><pub-id pub-id-type="pmid">18506009</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>ER</given-names></name><name><surname>von Segesser</surname><given-names>LK</given-names></name></person-group><article-title>Arterial grafting for myocardial revascularization: how better is
it?</article-title><source>Curr Opin Cardiol</source><year>2006</year><volume>21</volume><issue>6</issue><fpage>584</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">17053408</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayward</surname><given-names>PA</given-names></name><name><surname>Buxton</surname><given-names>BF</given-names></name></person-group><article-title>Mid-term results of the Radial Artery Patency and Clinical
Outcomes randomized trial</article-title><source>Ann Cardiothorac Surg</source><year>2013</year><volume>2</volume><issue>4</issue><fpage>458</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">23977623</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudzinski</surname><given-names>P</given-names></name><name><surname>Wegrzyn</surname><given-names>P</given-names></name><name><surname>Lis</surname><given-names>GJ</given-names></name><name><surname>Piatek</surname><given-names>J</given-names></name><name><surname>Konstanty-Kalandyk</surname><given-names>J</given-names></name><name><surname>Nosalski</surname><given-names>R</given-names></name><etal/></person-group><article-title>Vasodilatory effect and endothelial integrity in papaverine- and
milrinone-treated human radial arteries</article-title><source>J Physiol Pharmacol</source><year>2013</year><volume>64</volume><issue>1</issue><fpage>41</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">23568970</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mussa</surname><given-names>S</given-names></name><name><surname>Guzik</surname><given-names>TJ</given-names></name><name><surname>Black</surname><given-names>E</given-names></name><name><surname>Dipp</surname><given-names>MA</given-names></name><name><surname>Channon</surname><given-names>KM</given-names></name><name><surname>Taggart</surname><given-names>DP</given-names></name></person-group><article-title>Comparative efficacies and durations of action of
phenoxybenzamine, verapamil/nitroglycerin solution, and papaverine as
topical antispasmodics for radial artery coronary bypass
grafting</article-title><source>J Thorac Cardiovasc Surg</source><year>2003</year><volume>126</volume><issue>6</issue><fpage>1798</fpage><lpage>1805</lpage><pub-id pub-id-type="pmid">14688690</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzik</surname><given-names>TJ</given-names></name><name><surname>West</surname><given-names>NE</given-names></name><name><surname>Pillai</surname><given-names>R</given-names></name><name><surname>Taggart</surname><given-names>DP</given-names></name><name><surname>Channon</surname><given-names>KM</given-names></name></person-group><article-title>Nitric oxide modulates superoxide release and peroxynitrite
formation in human blood vessels</article-title><source>Hypertension</source><year>2002</year><volume>39</volume><issue>6</issue><fpage>1088</fpage><lpage>1094</lpage><pub-id pub-id-type="pmid">12052847</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapira</surname><given-names>OM</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name><name><surname>Aldea</surname><given-names>GS</given-names></name><name><surname>Vita</surname><given-names>JA</given-names></name><name><surname>Shemin</surname><given-names>RJ</given-names></name><name><surname>Keaney Jr</surname><given-names>JF</given-names></name></person-group><article-title>Enhanced nitric oxide-mediated vascular relaxation in radial
artery compared with internal mammary artery or saphenous
vein</article-title><source>Circulation</source><year>1999</year><volume>100</volume><issue>19</issue><supplement>Suppl</supplement><fpage>II322</fpage><lpage>II327</lpage><pub-id pub-id-type="pmid">10567323</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><article-title>Effect of milrinone on cardiac functions in patients undergoing
coronary artery bypass graft: a meta-analysis of randomized clinical
trials</article-title><source>Drug Des Devel Ther</source><year>2016</year><volume>10</volume><fpage>53</fpage><lpage>58</lpage></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Cascales</surname><given-names>J</given-names></name></person-group><article-title>Resveratrol enhances the inotropic effect but inhibits the
proarrhythmic effect of sympathomimetic agents in rat
myocardium</article-title><source>Peer J</source><year>2017</year><volume>5</volume><elocation-id>e3113</elocation-id><pub-id pub-id-type="pmid">28382232</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>G</given-names></name><name><surname>Yamaguchi</surname><given-names>S</given-names></name><name><surname>Takagi</surname><given-names>T</given-names></name><name><surname>Tomita</surname><given-names>S</given-names></name><name><surname>Tuan</surname><given-names>PM</given-names></name></person-group><article-title>Potent vasodilatory effect of fasudil on radial artery graft in
coronary artery bypass operations</article-title><source>Ann Thorac Surg</source><year>2014</year><volume>97</volume><issue>3</issue><fpage>845</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">24286636</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiessling</surname><given-names>AH</given-names></name><name><surname>Romasku</surname><given-names>D</given-names></name><name><surname>Beiras-Fernandez</surname><given-names>A</given-names></name><name><surname>Ferreir&#x000f3;s</surname><given-names>N</given-names></name><name><surname>Labocha</surname><given-names>S</given-names></name><name><surname>Moritz</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pharmacokinetics of intraluminally administered serum papaverine
for spasm prophylaxis of the internal mammary artery</article-title><source>Heart Surg Forum</source><year>2013</year><volume>16</volume><issue>5</issue><fpage>E266</fpage><lpage>E270</lpage><pub-id pub-id-type="pmid">24217241</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenfeldt</surname><given-names>FL</given-names></name><name><surname>He</surname><given-names>GW</given-names></name><name><surname>Buxton</surname><given-names>BF</given-names></name><name><surname>Angus</surname><given-names>JA</given-names></name></person-group><article-title>Pharmacology of coronary artery bypass grafts</article-title><source>Ann Thorac Surg</source><year>1999</year><volume>67</volume><issue>3</issue><fpage>878</fpage><lpage>888</lpage><pub-id pub-id-type="pmid">10215263</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motallebzadeh</surname><given-names>R</given-names></name><name><surname>Wendler</surname><given-names>O</given-names></name></person-group><article-title>Reactivity of the human internal thoracic artery to vasodilators
in coronary artery bypass grafting</article-title><source>Eur J Cardiothorac Surg</source><year>2005</year><volume>28</volume><issue>4</issue><fpage>661</fpage><lpage>662</lpage><pub-id pub-id-type="pmid">16125402</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e4;yr&#x000e4;np&#x000e4;&#x000e4;</surname><given-names>M</given-names></name><name><surname>Simpanen</surname><given-names>J</given-names></name><name><surname>Hess</surname><given-names>MW</given-names></name><name><surname>Werkkala</surname><given-names>K</given-names></name><name><surname>Kovanen</surname><given-names>PT</given-names></name></person-group><article-title>Arterial endothelial denudation by intraluminal use of
papaverine-NaCl solution in coronary bypass surgery</article-title><source>Eur J Cardiothorac Surg</source><year>2004</year><volume>25</volume><issue>4</issue><fpage>560</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">15037272</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Sayed</surname><given-names>MI</given-names></name><name><surname>Amin</surname><given-names>HA</given-names></name></person-group><article-title>Mechanism of endothelial cyto-protective and thrombo-resistance
effects of sildenafil, vardenafil and tadalafil in male
rabbit</article-title><source>Arch Med Sci</source><year>2015</year><volume>11</volume><issue>1</issue><fpage>190</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">25861307</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>LM</given-names></name><name><surname>Galvin</surname><given-names>SD</given-names></name><name><surname>Javid</surname><given-names>M</given-names></name><name><surname>Matalanis</surname><given-names>G</given-names></name></person-group><article-title>Should the radial artery be used as a bypass graft following
radial access coronary angiography</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2014</year><volume>18</volume><issue>2</issue><fpage>219</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">24254539</pub-id></element-citation></ref></ref-list></back></article>